Clinical Trial Update: CD34+ Selected ASCT for Aggressive Lymphomas [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 clinical trial evaluating CD34+ selected autologous stem cell transplantation for aggressive non-Hodgkin lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• CD34+ selected autologous stem cell transplantation

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Malignant Non-Hodgkin Lymphomas | Phase 2 | Status: COMPLETED